Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.4 USD +9.59% Intraday chart for Lexicon Pharmaceuticals, Inc. -0.41% +56.86%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering MT
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients MT
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease CI
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup DJ
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Decline in Afternoon Trading MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Jump MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell MT
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin DJ
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q4 Revenue $702,000 MT
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Lexicon Pharmaceuticals, Inc Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA CI
Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding CI
Transcript : Lexicon Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM
Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference CI
Lexicon Pharmaceuticals, Inc. and Lexicon Pharmaceuticals (New Jersey), Inc Enter into Fourth Amendment to its Loan and Security Agreement with Oxford Finance LLC CI
Lexicon Enrolls First Patient in Phase 2b Trial of Potential Non-Opioid Drug for Diabetic Neuropathic Pain MT
Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain CI
Lexicon Says Phase 3 Data of Sotagliflozin Show Risk Reductions in Heart Failure, Major Adverse Cardiovascular Events MT
Lexicon Pharmaceuticals, Inc. Announces Post Hoc Analysis of Clinical Data from the SCORED Trial CI
Transcript : Lexicon Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q3 Revenue $162,000 MT
Lexicon Pharmaceuticals' Inpefa Placed on Express Scripts' Basic, High Performance Formularies MT
Chart Lexicon Pharmaceuticals, Inc.
More charts
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.4 USD
Average target price
5.5 USD
Spread / Average Target
+129.17%
Consensus
  1. Stock
  2. Equities
  3. Stock Lexicon Pharmaceuticals, Inc. - Nasdaq
  4. News Lexicon Pharmaceuticals, Inc.
  5. Lexicon Pharmaceuticals : Begins Dosing Patients in Phase 2 Study of LX9211 to Treat Post-Herpetic Neuralgia